BROADCASTS.com

The Pfizer/BioNTech coronavirus vaccination approved in the UK requires four weeks from the first jab for the "best immunity" to be achieved, regulators behind the decision have said.
Meanwhile, those who are first to receive the vaccination will be invited to take part in a voluntary "Yellow Card" monitoring program for side effects.
On Wednesday the UK Medicines and Healthcare products Regulatory Agency (MHRA) became the first in the world to approve a Covid-19 vaccination for widespread use with the first doses to be delivered in days.
Leeds University virus expert Stephen Griffin told Mike Hosking the vaccine is a phenomenal scientific achievement.
"It really is fantastic news that we have, in space of less than a year, been able to access a vaccine against the pandemic." 
But he says he UK can't be complacent.
"We're only going to be contacting a fraction of the population. We still have very high levels of community transmission. We're seeing very high numbers of deaths every day."
Chief Executive Dr June Raine insisted no "corners had been cut" in the approval process and assured the public the decision had been reached following an "extremely thorough and scientifically rigorous review" of the vaccine's safety, effectiveness and quality.
"The safety of the public will always come first," she said, adding that the MHRA had completed a "rolling review" to achieve approval in the shortest-time possible.
She described the process as like climbing a mountain which began in June.
"By the time the interim results came in November, we were at base camp," Raine said, describing the final stretch as a "sprint."
Professor Sir Munir Pirmohamed said immunisation will require two doses 21 days apart.
While "some immunity" is seen 12 days after the first dose, the "best immunity" comes seven days after the second dose, meaning it will be a total of four weeks before people can consider themselves safe from the virus.
Raine thanked those who had enlisted in clinical trials and said they will now be "inviting members of the public to join us in an active monitoring programme" for any potential side-effects.
Monitoring will be based on the existing Yellow Card system in the UK that allows people to report side effects of any drugs or medical devices. The scheme relies on voluntary reporting to flag any early warning signs that may warrant further investigation.
"We still do not know how Covid-19 interacts and behaves with medicines or medical devices used for existing conditions," the site warns under its Covid page.
"By reporting through this site, patients and healthcare professionals can help gather valuable evidence to inform decisions on the safe and effective use of medicines and medical devices as the pandemic evolves."
Guidance on the vaccine states that "most side effects are mild or moderate and go away within a few days of appearing".
Ones dubbed "very common" affecting more than one in 10 people include

pain at injection site
tiredness
headache
muscle pain
chills
joint pain
fever

Other side affects dubbed "common" affecting up to 1 in 10 include

injection site swelling
redness at injection site
nausea

While "uncommon" ones that may affect up to 1 in 100 people include:

enlarged lymph nodes
feeling unwell

WHO WILL GET IT FIRST?
The vaccine will be first given to those seen as at most risk of dying from the disease, including elderly, those with pre-existing conditions and frontline healthcare workers before a major public rollout.
That means care home residents will be first, followed by those over 80 and NHS workers, then those over age 75, followed by those over 70 and people with conditions that make them clinically vulnerable, and so on in five-year age brackets.
The next phase will involve general public deployment of the vaccine for those aged 16 and over that will be carried out by local authorities.
However, the vaccine is "not recommended" for children under 16. Women that are pregnant or breastfeeding...